Legal and Ethical Considerations in Peptide Use for Athletes

Where MOTS-c and SS-31 Stand With WADA

The two mitochondrial peptides athletes ask about most, MOTS-c and SS-31 (elamipretide), are in very different positions on the anti-doping list. An earlier version of this page put both under S0, WADA's class for non-approved substances. That was wrong for MOTS-c then and is uncertain for SS-31 now.

MOTS-c: named under S4.4.1

WADA's 2026 Prohibited List, in force since January 1, 2026, names MOTS-c directly. It sits in S4.4.1, metabolic modulators, as an example of an activator of AMP-activated protein kinase (AMPK), next to AICAR and BAM15. The list states that S4.3 and S4.4 substances are non-Specified and prohibited at all times, in and out of competition.

The non-Specified label matters. Under the World Anti-Doping Code, non-Specified substances carry heavier default sanctions than Specified ones (BPC-157, an S0 substance, is Specified). An athlete who tests positive for MOTS-c starts from the tougher end of the sanction range. USADA's athlete advisory for the 2027 List also reminds athletes that they are strictly liable for whatever is in their system, so "I thought it was a supplement" is not a defense.

For UFC fighters, testing has been run by Combat Sports Anti-Doping (CSAD) since early 2024, not USADA. The UFC Anti-Doping Policy follows the WADA list and its Specified labels, so MOTS-c is treated as a non-Specified substance there too. USADA still runs testing for US Olympic and Paralympic athletes.

SS-31: approved drug, unclear status

SS-31 is not named anywhere on the 2026 list. Before 2025 it would have fallen under S0, which covers any pharmacological substance not addressed elsewhere on the list "and with no current approval by any governmental regulatory health authority for human therapeutic use."

That changed on September 19, 2025, when the FDA granted accelerated approval to Forzinity (elamipretide) for Barth syndrome, a rare mitochondrial disease. Because elamipretide now has a current approval, the S0 test no longer clearly applies. Whether WADA would place it under another class, such as the S4.4 metabolic modulators, is unverified. As of October 2026 we found no WADA or USADA statement on elamipretide's status since approval, and we aren't going to guess.

What this means in practice: an unclear status is not a green light. USADA's 2027 advisory says the 2027 List, which takes effect January 1, 2027, names "peptides" in general as examples in S0, and warns that a peptide can be prohibited even when it isn't named on Global DRO. A tested athlete considering SS-31 should get a written answer from their anti-doping organization first. A Barth syndrome patient prescribed Forzinity would go through the therapeutic use exemption process, which is a separate question from performance use.

The regulatory history is covered in more depth in our page on the legal landscape for mitochondrial peptides in sport.

US Law for Athletes Who Aren't Tested

For lifters outside tested federations, WADA rules don't apply, but US drug law still does. The short version: buying these peptides is not usually a crime for the buyer, but nothing about the gray-market supply is lawful or regulated in the way an approved medicine is.

The "research use only" label

Both peptides are sold online as "research use only, not for human consumption." FDA does not treat that label as a shield. In its August 24, 2026 warning letter to Tex Peptides, FDA named "SS-31 (Elamipretide)" among products it called unapproved new drugs, and wrote that despite the research-only labeling, evidence from the website showed the products were intended as drugs for human use. Selling bacteriostatic water alongside the peptides counted as part of that evidence, because it supplies the means to prepare an injection. As of October 2026, enforcement has targeted sellers, not individual buyers.

For the buyer, the practical problem is quality. Nobody at FDA checks whether a research vial holds the stated peptide at the stated dose, or whether it is sterile. You are relying on the seller's own certificate of analysis, and our page on how peptide synthesis affects purity explains why those vary.

SS-31 vials are not Forzinity

Forzinity is a prescription medicine. Its FDA label limits it to adults and children with Barth syndrome weighing at least 30 kg, at 40 mg by subcutaneous injection once daily. The label's clinical program included 12 male patients, and FDA requires a confirmatory randomized trial. A vial sold online as "SS-31" is not the approved product and wasn't made under its manufacturing controls. FDA's warning letters treat it as an unapproved drug. The fact that elamipretide is approved for a rare disease says nothing about the safety of a gray-market vial used by a healthy athlete.

MOTS-c and compounding

MOTS-c is not approved anywhere, and as of October 2026 it isn't a controlled substance. In July 2026, FDA's pharmacy compounding advisory committee voted 7 to 5 to recommend MOTS-c for the 503A bulks list, which would let pharmacies compound it. That vote is advisory. FDA has not started rulemaking, so there is still no lawful compounded MOTS-c in the US.

Outside the US, regulators have been blunter. Health Canada's April 2026 advisory on unauthorized injectable peptides lists both MOTS-c and SS-31 among products consumers should avoid.

The Ethical Questions

The legal picture tells you what can happen to you. The ethical questions are about what you're actually agreeing to, and what it does to the people you compete against.

Safety: the data gap is wide for MOTS-c

Most of what is known about MOTS-c comes from mice. The 2015 Cell Metabolism study that described it showed improved insulin sensitivity and protection against diet-induced obesity in mice. As of October 2026, no peer-reviewed study has given native MOTS-c to people. The closest human data is a Phase 1a/1b study of CB4211, a modified analog from CohBar, which is a different molecule. The only registry entry for a Phase 2 trial of native MOTS-c comes from a sponsor whose records are disputed. Users report injection-site welts and itching, and some report noticing nothing at all; none of this has been measured in a study. A fuller account is in our MOTS-c overview.

SS-31 has more human data, but almost all of it is in sick patients. In the Barth syndrome program, injection-site reactions were the most common side effect, and the Forzinity label warns of serious allergic reactions, some needing emergency treatment. FDA approved it on a surrogate measure (knee strength) that it considers reasonably likely to predict benefit, not on proof of benefit. No study has looked at healthy athletes, and none has followed users for years; our page on long-term health implications covers what that leaves unanswered.

Informed consent

Consent means understanding the risk you're taking. With MOTS-c, nobody can describe that risk in humans, and with any gray-market vial you can't be sure what's inside. That limits how informed any decision can be. The concern is sharper when a coach or older training partner supplies peptides to younger athletes, who may not know about strict liability or the missing safety data.

Fairness

In tested sport, using MOTS-c breaks rules every competitor agreed to, whatever its real effect turns out to be. SS-31's unsettled status doesn't make it fair game; it means the rule hasn't been clarified. In untested federations the fairness question is mostly about honesty: whether the federation's own rules permit it, and whether you'd be comfortable disclosing what you use.

What We Still Don't Know

• How WADA will treat elamipretide now that it is an approved drug, and whether a ruling will appear before the 2027 List takes effect.
• Whether FDA will act on the July 2026 committee vote and add MOTS-c to the 503A bulks list.
• Whether Forzinity's confirmatory trial shows real patient benefit.
• Whether anyone will publish a verified human study of native MOTS-c.